Rare Disease Treatment
Auto-discovered topic: Rare Disease Treatment
3 articles analyzed- BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment Propaganda: 10%
- Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio Propaganda: 10%
- Precision DNA editing targets root cause of severe childhood epilepsy in preclinical study Propaganda: 10%